- To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany
Marlborough, Massachusetts–(Newsfile Corp. – April 3, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio today announced that podium presentations will be given on its two lead INTASYL product candidates, PH-762 and PH-894.
The ITOC conference provides a unique platform for the exchange of latest findings in immunotherapy of cancer to advance oncology drug development and delivery.
Melissa Maxwell, Phio’s Director of Research and Program Management, was awarded two speaker presentations, as follows:
Plenary Session 3: New Targets and New Leads
Date and Time: April 3, 2025, 16.30 – 16.45 PM (CEST)
Title: Targeting PD-1 with self-delivering RNAi: preclinical advances and ongoing clinical evaluation in intratumoral Immunotherapy
PH-762, an INTASYL siRNA compound targeting PD-1, is being evaluated in an ongoing clinical trial (NCT 06014086) as a neoadjuvant intratumoral therapy for cutaneous malignancies, demonstrating promising preclinical efficacy, favorable tolerability, and the potential to enhance immune responses while minimizing systemic side effects.
Plenary Session 11: What Cellular Therapies Need to Work
Date and Time: April 5, 2025, 12.15 – 12.30 PM (CEST)
Title: Silencing BRD4 to increase NK cell activity for adoptive cell therapy: a novel self- delivering RNAi approach
PH-894, an INTASYL siRNA compound, selectively silences BRD4, a key regulator of gene expression. PH-894 enhances NK cell activation and proliferation without off-target effects, presenting a promising strategy to improve adoptive cell therapy.
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio’s INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
For additional information, visit the Company’s website, www.phiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-Looking statements can be identified by words such as “intends,” “believes,” “anticipates,” “indicates,” “plans,” “expects,” “suggests,” “may,” “would,” “should,” “potential,” “designed to,” “will,” “ongoing,” “estimate,” “forecast,” “target,” “predict,” “could” and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body’s immune cells more effective in killing cancer cells and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.
These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors” and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.
Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246881